NCT07133308: Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
- State
- Under way
- Phase
- Phase 3
- People
- 355 planned
- Started
- 5 Aug 2025
- Primary completion
- May 2028
- Arms
- Treatment Period: Deuruxolitinib 8 mg, Open-Label Extension: Deuruxolitinib 8 mg BID
- Results
- None posted
- 5 Aug 2025: Trial started
- 21 Aug 2025: Trial registered